**Question:** Which of the following is active against atypical mycobacteria -

A. Ethambutol
B. Isoniazid
C. Rifampicin
D. Amikacin

**Core Concept:**
Atypical mycobacteria are non-tuberculous mycobacteria that can cause infections in humans. They are usually resistant to first-line anti-TB drugs, such as Ethambutol (EBA) and Isoniazid (HBA), but may be susceptible to second-line drugs like Rifampicin (RBA) and Amikacin (ABA).

**Why the Correct Answer is Right:**
The correct answer, Amikacin (ABA), is a second-line anti-TB drug that demonstrates activity against atypical mycobacteria. ABA belongs to the aminoglycoside class of antibiotics, which target the ribosome and inhibit protein synthesis in bacteria, leading to cell death.

**Why Each Wrong Option is Incorrect:**
A. Ethambutol (EBA) is a first-line drug used in standard TB treatment but is not effective against atypical mycobacteria due to its specific mechanism of action targeting arabinosyltransferase enzymes involved in cell wall synthesis.
B. Isoniazid (HBA) is also a first-line anti-TB drug, targeting mycobacterial enzymes involved in cell wall synthesis. However, its activity against atypical mycobacteria is limited due to their resistance mechanisms.
C. Rifampicin (RBA) is a first-line drug targeting the RNA polymerase enzyme in bacteria, but its mechanism does not specifically address the resistance mechanisms of atypical mycobacteria, making it less effective against them.

**Clinical Pearl:**
Atypical mycobacterial infections are often challenging to treat due to their resistance patterns. Combination therapy involving drugs like Amikacin, Ethambutol, and Rifampicin is often required for effective treatment, while Isoniazid is usually not a primary choice for atypical mycobacteria treatment.

**Core Concept:**
Atypical mycobacteria, including Mycobacterium avium complex (MAC) and Mycobacterium abscessus, can cause infections in immunocompromised patients or in areas with high prevalence of TB.

**Why Each Wrong Option is Incorrect:**
A. Ethambutol (EBA) is primarily effective against Mycobacterium tuberculosis but has limited activity against atypical mycobacteria due to their resistance mechanisms.
B. Isoniazid (HBA) has limited activity against atypical mycobacteria as it targets mycobacterial enzymes involved in cell wall synthesis, which is common to both Mycobacterium tuberculosis and atypical mycobacteria.
C. Rifampicin (RBA) is effective against Mycobacterium tuberculosis but has limited activity against atypical mycobacteria due to their resistance mechanisms.
D. Amikacin (ABA) is a second-line antibiotic effective against both Mycobacterium tuberculosis and atypical mycobacteria. Its effectiveness against